Body PSOriasis: Long-term Relapse CONTROL (PSO-CONTROL)

LEO Pharma

Status: Completed

Conditions: Psoriasis Vulgaris

Treatments: Drug: Any topical drug treatment

Study type: Observational

Funder types: Industry

Identifiers

NCT03402828

NIS-PSORIASIS-1379

Details and patient eligibility

About

This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.

Enrollment: 764 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients planned to receive topical treatment of any kind to prevent relapse of symptoms
• Written informed consent

Exclusion criteria

• Contraindications to selected treatment
• Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or phototherapy